Chime Biologics Announces Strategic Cooperation with Leads Biolabs and BeiGene to Advance LBL-007 mAb Development and Manufacturing Globally

On June 30, 2023 Chime Biologics, a leading CDMO that enables its partners’ success in biologics, reported that it has established 3-way strategic cooperation with Leads Biolabs and BeiGene to accelerate LBL-007 mAb development and manufacturing for speedy clinical advancement (Press release, Nanjing Leads Biolabs, JUN 30, 2023, View Source [SID1234633014]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

LBL-007 is a novel antibody targeting the LAG-3 pathway developed independently by Leads Biolabs. The phase I clinical trial data of LBL-007 in patients with later-stage solid tumors have been announced at the 2021 annual meeting of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper).

Previously, Leads Biolabs and BeiGene reached an authorization and cooperation agreement. Leads Biolabs grants LBL-007 exclusive global development and production license to BeiGene, as well as a commercial manufacturing license outside China.

Leads Biolabs and Chime Biologics initiate strategic cooperation to accelerate IND application and provide clinical trial materials in China.

Leads Biolabs has entrusted Chime Biologics with the file supporting work related to the production of LBL-007 project and clinical trial materials in mainland China. Now, the project is progressing into clinical phase II stage. At 2023 ASCO (Free ASCO Whitepaper) conference in Chicago from June 2 to 6, Leads Biolabs presented a poster summarizing the latest clinical data research results on safety and efficacy of anti-LAG-3 (lymphocyte activating gene-3) antibody LBL-007 in the treatment of advanced or metastatic melanoma. This is an open-label, multicenter, dose-escalation or expansion Phase I clinical trial research conducted in China, focusing on safety, RP2D, pharmacokinetics and pharmacodynamics.

BeiGene and Chime Biologics establish strategic cooperation to facilitate IND applications overseas and clinical trial materials supply.

BeiGene is also entrusting Chime Biologics to provide support for clinical development and manufacturing of clinical trial materials in order to facilitate multiple clinical trials. The indications encompass colorectal cancer, non-small cell lung cancer, head and neck squamous cell carcinoma, as well as other solid tumors. Clinical trials have been conducted in numerous countries worldwide, including Australia and the United States.

The three parties have established a comprehensive strategic partnership based on the principle of "Complementary Advantages, Resource Sharing, Strong Alliance, and Win-win Cooperation". Through 3-way cooperation, multiple clinical studies are advancing rapidly based on the global development distribution of LBL-007. We hope anti-LAG-3 antibodies can bring good news to cancer patients as soon as possible.

A Trusted Partner in Biologics Commercial Manufacturing

Chime Biologics serves as a long-term partner to biopharmaceutical clients with sound solutions for manufacturing and more recently moved into late stage and commercial manufacturing. We support various stages of new drug registration and application, provide production service for preclinical, clinical and listed drugs, including non-GMP standard production and the first modular biopharmaceutical factory in the world which meets the global cGMP standards.

Dr. Kang Xiaoqiang, Founder, Chairman and CEO of Leads Biolabs, stated: "We are so pleased to cooperate with BeiGene, a global leading enterprise in oncology field, and Chime Biologics with extensive antibody production experience. LBL-007 is the first innovative antibody drug with global intellectual property which we developed independently. I believe that the development and commercialization of LBL-007 can be expedited through our triangular cooperation, so we can address unmet medical needs and bring hope to cancer patients."

Dr. Wang Lai, Global R&D Director of BeiGene, said: "The clinical candidate drug developed by Leads Biolabs has a broad prospect, not only enriching our tumor immunotherapy drug pipeline but also supporting us for global clinical development strategic priorities and development opportunities. Chime Biologics has advanced drug commercial manufacturing experience, a sound quality system and efficient production management, providing assurance of LBL-007 for global development. Although the cooperation is not too long, LBL-007 has launched nearly ten Phase I and II clinical trials worldwide in the last year, with indications covering colorectal cancer, non-small cell lung cancer, head and neck squamous cell cancer, melanoma and other solid tumor cancers. I believe that this cooperation will bring new opportunities for the medical community to further conquer cancer."

Dr. Wei Jianzhong, President of Chime Biologics, stated:" We are glad to be the partner of these two leading Biopharma enterprises to provide the IND filing support of LBL-007 project and clinical trial materials production. The three parties will work together to deepen cooperation and promote the clinical trial process of LBL-007 project. Chime Biologics has always focused on quality management and technological innovation. This cooperation project is a remarkable milestone of company’s global development. We are very proud to be able to empower biopharma partners to bring more drugs to the market as soon as possible and benefit patients worldwide."

About LBL-007

LBL-007 is a fully humanized anti-LAG-3 (lymphocyte activating gene-3) monoclonal IgG4 antibody consisting of two IgG4 heavy chains and two κ light chains linked by disulfide bonds, with high affinity to human LAG-3, and exerts antitumor effects by blocking LAG-3 activation of immune function. In preclinical models, LBL-007 in combination with anti-programmed cell death protein 1 (PD-1) showed synergistic antitumor activity. Results from the phase I a study of LBL-007 monotherapy have been published in ASCO (Free ASCO Whitepaper) 2021 (Abstract 2523); preliminary safety and efficacy data for LBL-007 combined with toripalimab in patients with advanced melanoma (Part A) have been reported in ASCO (Free ASCO Whitepaper) 2022 (Abstract 9538/Poster 131), showing a favorable safety profile and better antitumor activity, particularly in anti PD-(L)1 naïve patients with acral melanoma. Several clinical studies of LBL-007 are currently in rapid progress based on global layout.